Drug | Tablet
Glimepiride 2 mg + Metformin (Modified Release) 500 mg + Voglibose 0.2 mg
Type 2 diabetes mellitus, Control of post‑meal (postprandial) blood glucose in type 2 diabetes when diet and exercise alone are insufficient
Glimepiride increases insulin release from the pancreas and improves insulin sensitivity. Metformin reduces glucose production in the liver and improves peripheral glucose uptake. Voglibose delays intestinal carbohydrate absorption, reducing post‑meal glucose spikes.
Take exactly as prescribed. Usually taken once daily with/just before the first main meal; swallow tablet whole (do not crush/chew, especially for modified‑release metformin). Monitor blood glucose regularly and follow diet/exercise advice.
Common side effects of Glimda Mv 2 Tablet may include:
Risk of hypoglycaemia (especially with missed meals, excess exercise, alcohol, or other antidiabetics). Metformin may rarely cause lactic acidosis—risk increased in kidney impairment, dehydration, severe infection, heart/liver failure, or excessive alcohol; stop and seek urgent care if severe weakness, fast breathing, abdominal pain, or unusual sleepiness occurs. Avoid in severe renal impairment; periodic kidney function monitoring required. Temporarily withhold metformin around iodinated contrast procedures and major surgery as advised by doctor. Use caution in elderly and in people with irregular eating habits.
